192 related articles for article (PubMed ID: 7867008)
1. Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization.
Dreyling MH; Bohlander SK; Adeyanju MO; Olopade OI
Cancer Res; 1995 Mar; 55(5):984-8. PubMed ID: 7867008
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene.
Wiest JS; Franklin WA; Otstot JT; Forbey K; Varella-Garcia M; Rao K; Drabkin H; Gemmill R; Ahrent S; Sidransky D; Saccomanno G; Fountain JW; Anderson MW
Cancer Res; 1997 Jan; 57(1):1-6. PubMed ID: 8988029
[TBL] [Abstract][Full Text] [Related]
3. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
Balázs M; Carroll P; Kerschmann R; Sauter G; Waldman FM
Genes Chromosomes Cancer; 1997 Jun; 19(2):84-9. PubMed ID: 9171998
[TBL] [Abstract][Full Text] [Related]
4. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies.
Dreyling MH; Bohlander SK; Le Beau MM; Olopade OI
Blood; 1995 Sep; 86(5):1931-8. PubMed ID: 7544647
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
6. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
[TBL] [Abstract][Full Text] [Related]
7. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.
Ohta M; Nagai H; Shimizu M; Rasio D; Berd D; Mastrangelo M; Singh AD; Shields JA; Shields CL; Croce CM
Cancer Res; 1994 Oct; 54(20):5269-72. PubMed ID: 7923152
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas.
Olopade OI; Jenkins RB; Ransom DT; Malik K; Pomykala H; Nobori T; Cowan JM; Rowley JD; Diaz MO
Cancer Res; 1992 May; 52(9):2523-9. PubMed ID: 1568221
[TBL] [Abstract][Full Text] [Related]
9. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).
Schmid M; Malicki D; Nobori T; Rosenbach MD; Campbell K; Carson DA; Carrera CJ
Oncogene; 1998 Nov; 17(20):2669-75. PubMed ID: 9840931
[TBL] [Abstract][Full Text] [Related]
10. A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer.
Schmid M; Sen M; Rosenbach MD; Carrera CJ; Friedman H; Carson DA
Oncogene; 2000 Nov; 19(50):5747-54. PubMed ID: 11126361
[TBL] [Abstract][Full Text] [Related]
11. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma.
Sonoda Y; Yoshimoto T; Sekiya T
Oncogene; 1995 Nov; 11(10):2145-9. PubMed ID: 7478535
[TBL] [Abstract][Full Text] [Related]
12. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.
Packenham JP; Taylor JA; White CM; Anna CH; Barrett JC; Devereux TR
Clin Cancer Res; 1995 Jul; 1(7):687-90. PubMed ID: 9816033
[TBL] [Abstract][Full Text] [Related]
13. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
14. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations.
Simoneau AR; Spruck CH; Gonzalez-Zulueta M; Gonzalgo ML; Chan MF; Tsai YC; Dean M; Steven K; Horn T; Jones PA
Cancer Res; 1996 Nov; 56(21):5039-43. PubMed ID: 8895761
[TBL] [Abstract][Full Text] [Related]
15. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
Schultz DC; Vanderveer L; Buetow KH; Boente MP; Ozols RF; Hamilton TC; Godwin AK
Cancer Res; 1995 May; 55(10):2150-7. PubMed ID: 7743516
[TBL] [Abstract][Full Text] [Related]
16. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
Pollock PM; Pearson JV; Hayward NK
Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
Dreyling MH; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink HK; Bentz M; Hiddemann W; Döhner H
Cancer Res; 1997 Oct; 57(20):4608-14. PubMed ID: 9377576
[TBL] [Abstract][Full Text] [Related]
18. Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia.
Coleman A; Fountain JW; Nobori T; Olopade OI; Robertson G; Housman DE; Lugo TG
Cancer Res; 1994 Jan; 54(2):344-8. PubMed ID: 8275465
[TBL] [Abstract][Full Text] [Related]
19. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions.
Cairns P; Okami K; King P; Bonacum J; Ahrendt S; Wu L; Mao L; Jen J; Sidransky D
Cancer Res; 1997 Dec; 57(23):5356-9. PubMed ID: 9393760
[TBL] [Abstract][Full Text] [Related]
20. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
Brenner AJ; Aldaz CM
Cancer Res; 1995 Jul; 55(13):2892-5. PubMed ID: 7796417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
